Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, multinational, randomised, open study to establish the optimal method for initiating Lantus (insulin glargine) therapy to determine metabolic and economic outcomes, safety, and satisfaction in subjects with type 2 diabetes mellitus.

Trial Profile

A multicentre, multinational, randomised, open study to establish the optimal method for initiating Lantus (insulin glargine) therapy to determine metabolic and economic outcomes, safety, and satisfaction in subjects with type 2 diabetes mellitus.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms INITIATE
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Apr 2018 Results of pooled analysis of Asian patients included in this and other six trials assessing the impact of patient baseline covariates on the required dose of basal insulin and treatment response for the improved management of Asian patients with type 2 diabetes published in the Diabetes Therapy
    • 18 Jul 2007 Status change
    • 25 Apr 2007 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top